

JAN 07 2003

Please type a plus sign (+) inside this box

+

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 1

Complete if Known

Application Number	09/942,117
Filing Date	August 30, 2001
First Named Inventor	A. MENRAD et al.
Group Art Unit	1644
Examiner Name	M. Haddad
Attorney Docket Number	SCH-1832

RECEIVED

JAN 08 2003

TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM- DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		Office ³	Number ⁴	Kind Code ⁵ (if known)				
	B1	WO	9958570	A	Eidgenoss....	11/18/1999		

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	G1	Argaves et al., "Amino Acid Sequence of the Human Fibronectin Receptor," <i>Journal of Cell Biology</i> , Rockefeller University Press, New York, US, Vol. 105, 1987, pp. 1183-1190.	
	C2	Takada et al., "The Primary Structure of the VLA-2/Collagen Receptor Alpha2 Subunit (Platelet GPIIb/IIIa): Homology to Other Integrins and the Presence of a Possible Collagen-Binding Domain," <i>Journal of Cell Biology</i> , Rockefeller University Press, New York, US, Vol. 109, No. 1, 07/01/1989, pp. 397-407.	
	C3	Garcia-Velasco et al., "Regulation of Monocyte Chemotactic Protein-1 Expression in Human Endometrial Stromal Cells by Integrin-Dependent Cell Adhesion," <i>Biology of Reproduction</i> , Vol. 61, No. 2, August 1999, pp. 548-552.	
	C4	Wagner et al., "Differentiation of Polymorphonuclear Neutrophils in Patients with Systemic Infections and Chronic Inflammatory Diseases: Evidence of Prolonged Life Span and de novo Synthesis of Fibronectin," <i>Journal of Molecular Medicine</i> , Vol. 78, No. 6, 2000, pp. 337-345.	
	C5	Castellani et al., "The Fibronectin Isoform Containing the ED-B Oncofetal Domain: A Marker of Angiogenesis," <i>International Journal of Cancer</i> , New York, NY, US, Vol. 59, No. 6, 12/04/1994, pp. 612-618.	
	C6	Hashimoto-Uoshima et al., "The Alternatively Spliced Domains E11B and E11A of Human Fibronectin Affect Cell Adhesion and Spreading," <i>Journal of Cell Science</i> , Vol. 110, No. 18, 1997, pp. 2271-2280.	

Examiner
Signature

M. Haddad

Date
Considered

5/27/03

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² See attached Kinds of U.S. Patent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.